Veracyte, Inc. is a global diagnostics company that provides high-value molecular tests to assist clinicians in diagnosing and treating various cancers, including thyroid, prostate, breast, bladder, and lung cancers, as well as interstitial lung diseases. Their tests, such as the Afirma Genomic Sequencing Classifier for thyroid cancer and the Decipher Prostate and Bladder tests, use advanced genomic technologies and machine learning to provide actionable insights. These insights help avoid unnecessary procedures and personalize treatment plans, improving patient outcomes and care efficiency​. Veracyte Israel was established following the acquisition of Israeli cancer detection company C2i Genomics.